Muller S, Parker D C, Kapadia S B, Budnick S D, Barnes E L
Department of Pathology, University of Pittsburgh Medical Center, Pa., USA.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1995 Apr;79(4):469-77. doi: 10.1016/s1079-2104(05)80130-1.
Ameloblastic fibrosarcoma, the malignant counterpart of the ameloblastic fibroma, is a rare odontogenic tumor characterized by benign epithelium and a malignant fibrous stroma. We have compared nuclear DNA content of five ameloblastic fibrosarcomas and three ameloblastic fibromas by image analysis. The three ameloblastic fibromas were diploid, whereas 1 of 5 ameloblastic fibrosarcomas was aneuploid. There was no correlation with histologic grade and aneuploidy. These five new cases were also added to a review of the literature, bringing the total cases of reported ameloblastic fibrosarcomas to 51. The ameloblastic fibrosarcoma occurs at a later age (mean, 27.5 years) compared with reported ameloblastic fibromas (mean, 14.6 to 22 years), which supports a step-wise malignant transformation. There was histologic documentation that 44% of ameloblastic fibrosarcomas developed in ameloblastic fibromas. In view of this data and of the reported cumulative recurrence rate of 18.3% for ameloblastic fibroma, it is recommended that ameloblastic fibromas be treated with complete surgical excision and long-term follow up rather than simple curettage or enucleation.
成釉细胞纤维肉瘤是成釉细胞纤维瘤的恶性对应物,是一种罕见的牙源性肿瘤,其特征为良性上皮和恶性纤维性间质。我们通过图像分析比较了5例成釉细胞纤维肉瘤和3例成釉细胞纤维瘤的核DNA含量。3例成釉细胞纤维瘤为二倍体,而5例成釉细胞纤维肉瘤中有1例为非整倍体。组织学分级与非整倍体之间无相关性。这5例新病例也被纳入文献综述,使报道的成釉细胞纤维肉瘤病例总数达到51例。与报道的成釉细胞纤维瘤(平均14.6至22岁)相比,成釉细胞纤维肉瘤发病年龄较晚(平均27.5岁),这支持了其逐步恶性转化的观点。有组织学证据表明,44%的成釉细胞纤维肉瘤发生于成釉细胞纤维瘤。鉴于这些数据以及报道的成釉细胞纤维瘤18.3%的累积复发率,建议对成釉细胞纤维瘤进行完整手术切除并长期随访,而不是单纯刮除或摘除。